<DOC>
	<DOCNO>NCT00094835</DOCNO>
	<brief_summary>The purpose trial : - To characterize safety profile motesanib use combination carboplatin/paclitaxel ( CP ) , panitumumab CP panitumumab patient advance non-small cell lung cancer ( NSCLC ) . - To establish pharmacokinetic ( PK ) profile motesanib use combination CP , panitumumab , CP panitumumab . - To compare paclitaxel motesanib PK profile medication administer 30 minute ( min ) approximately 48 hour ( hr ) apart . - To characterize panitumumab paclitaxel exposure combination regimens motesanib CP , motesanib panitumumab , motesanib CP panitumumab . - To describe objective response rate ( ORR ) dose cohort . - To measure immunogenicity panitumumab patient administer motesanib panitumumab motesanib CP panitumumab .</brief_summary>
	<brief_title>Study Evaluate Motesanib With Without Carboplatin/Paclitaxel Panitumumab Treatment Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This multicenter , open-label , dose-finding clinical trial examine safety PK twice daily motesanib administered CP CP panitumumab chemotherapy na√Øve patient , panitumumab patient one prior chemotherapy regimen NSCLC . Participants enrol Panitumumab + Paclitaxel + Carboplatin + Motesanib safe tolerable dose AMG 706 establish treatment arm .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis unresectable stage IIIB IV nonsmall cell lung cancer ( NSCLC ) No one prior chemotherapy Adequate hematologic , renal hepatic function Measurable disease evaluable disease CAT scan MRI Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Able fast 10 hr twice study Able tolerate oral medication Life expectancy least 3 month Symptomatic untreated central nervous system metastases require current treatment History arterial thrombosis within 1 year prior enrollment Anticoagulant therapy , except warfarin le 2mg per day Symptomatic peripheral neuropathy History pulmonary hemorrhage hemoptysis Myocardial infarction within 1 year enrollment Uncontrolled hypertension [ diastolic great 85 mmHg ; systolic great 145 mmHg ] History cancer , unless treat know active disease longer 3 year Previous treatment AMG 706 panitumumab , previous treatment inhibitor VEGF EGF No antibody treatment 6 week prior enrollment Known HIV positive , hepatitis C positive hepatitis B surface antigen positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lung cancer , Non-small cell lung cancer , NSCLC</keyword>
	<keyword>Clinical Trial , Panitumumab , AMG 706</keyword>
	<keyword>Anti-angiogenesis</keyword>
	<keyword>Immunex , Abgenix , Amgen</keyword>
	<keyword>Stage IIIB , Stage IV , Unresectable</keyword>
</DOC>